Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2024 10:36 ET | Source: Starton Therapeutics

U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”

Olanzapine (ZYPREXA®) is an antipsychotic medication used to treat schizophrenia and bipolar disorder that is commonly used as anti-nausea off label medication.Olanzapine has been investigated for use...
February 23, 2024 14:48 ET | Source: Starton Therapeutics

Starton Therapeutics to Present at BIO CEO & Investor Conference 2024

PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
December 18, 2023 08:00 ET | Source: Starton Therapeutics

Starton Therapeutics to Present at Biotech Showcase 2024 in San Francisco

PARAMUS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (the “Company”) a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary...
November 20, 2023 08:00 ET | Source: Starton Therapeutics

Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment

Two patients have been dosed and a third is in screeningThe first patient has completed cycle 1 successfully where he obtained a measurable response with a decrease in M-protein from 1.7 to 0.9 gm/dL...